title: Relation of Longitudinal Changes in Quality of Life Assessments to Changes in Functional Capacity in Patients With Heart Failure With and Without Anemia.
abstract: Clinical status in heart failure is conventionally assessed by the physician's evaluation, patients' own perception of their symptoms, quality of life (QoL) tools, and a measure of functional capacity. These aspects can be measured with tools such as the New York Heart Association functional class, QoL tools such as the EuropeanQoL-5 dimension, the Kansas City Cardiomyopathy Questionnaire, patient global assessment (PGA), and by 6-minute walk test (6MWT), respectively. The ferric carboxymaltose in patients with heart failure and iron deficiency (FAIR-HF) trial demonstrated that treatment with intravenous ferric carboxymaltose in iron-deficient patients with symptomatic heart failure with reduced left ventricular function, significantly improved all 5 outcome measures. This analysis assessed the correlations between the longitudinal changes in the measures of clinical status, as measured by QoL tools and the changes in the measures of functional capacity as measured by the 6MWT. This analysis used the database from the FAIR-HF trial, which randomized 459 patients with chronic heart failure (reduced left ventricular ejection fraction) and iron deficiency, with or without anemia to ferrous carboxymaltose or placebo. The degree of correlation between QoL tools and the 6MWT was assessed at 4, 12, and 24 weeks. The data demonstrate highly significant correlations between QoL and functional capacity, as measured by the 6MWT, at all time points (p <0.001). Changes in PGA, Kansas City Cardiomyopathy Questionnaire, and EuroQoL-5D correlated increasingly over time with changes in 6MWT performance. Interestingly, the strongest correlation at 24 weeks is for the PGA, which is a simple numerical scale (r = -0.57, p <0.001). This analysis provides evidence that QoL assessment show a significant correlation with functional capacity, as measured by the 6MWT. The strength of these correlations increased over time.
authors.affiliation: Department of Cardiology, Stavanger University Hospital, Stavanger, Norway. Electronic address: trond.cooper@gmail.com.
authors.forename: Trond J
authors.initials: TJ
authors.lastname: Cooper
authors.affiliation: Innovative Clinical Trials, Department of Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany.
authors.forename: Stefan D
authors.initials: SD
authors.lastname: Anker
authors.affiliation: Heart Diseases Biomedical Research Group, Inflammatory and Cardiovascular Disorders Program, Hospital del Mar Medical Research Insititute, Parc de Salut Mar, Barcelona, Spain.
authors.forename: Josep
authors.initials: J
authors.lastname: Comin-Colet
authors.affiliation: Heart Failure Unit, Department of Cardiology, Athens University Hospital Attikon, Athens, Greece.
authors.forename: Gerasimos
authors.initials: G
authors.lastname: Filippatos
authors.affiliation: General Hospital Celje and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
authors.forename: Mitja
authors.initials: M
authors.lastname: Lainscak
authors.affiliation: Cardiology Department, University Hospital Zurich, Zurich, Switzerland.
authors.forename: Thomas F
authors.initials: TF
authors.lastname: Lüscher
authors.affiliation: Vifor Pharma, Glattbrugg, Switzerland.
authors.forename: Claudio
authors.initials: C
authors.lastname: Mori
authors.affiliation: JPharma Solutions, Bülach, Switzerland.
authors.forename: Patrick
authors.initials: P
authors.lastname: Johnson
authors.affiliation: Department of Cardiology, 4th Military Hospital, Wrocław, Poland; Clinic of Cardiac Diseases, Department of Heart Diseases, Medical University, Wrocław, Poland.
authors.forename: Piotr
authors.initials: P
authors.lastname: Ponikowski
authors.affiliation: Department of Cardiology, University of Bergen, Bergen, Norway.
authors.forename: Kenneth
authors.initials: K
authors.lastname: Dickstein
mesh_terms: D000368:Aged; D000740:Anemia / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D005080:Exercise Test; D017079:Exercise Tolerance / Q000502:physiology; D005260:Female; D005290:Ferric Compounds / Q000627:therapeutic use; D005500:Follow-Up Studies; D006333:Heart Failure / Q000150:complications / Q000503:physiopathology* / Q000523:psychology; D006397:Hematinics / Q000627:therapeutic use; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008320:Maltose / Q000031:analogs & derivatives / Q000627:therapeutic use; D008875:Middle Aged; D011788:Quality of Life; D020127:Recovery of Function / Q000502:physiology*; D057566:Self Report; D016896:Treatment Outcome
chemical_list: D005290:Ferric Compounds; D006397:Hematinics; C522335:ferric carboxymaltose; D008320:Maltose